Recurrent diffuse midline glioma, H3 K27M-mutant

Clinical trials for Recurrent diffuse midline glioma, H3 K27M-mutant explained in plain language.

Never miss a new study

Get alerted when new Recurrent diffuse midline glioma, H3 K27M-mutant trials appear

Sign up with your email to follow new studies for Recurrent diffuse midline glioma, H3 K27M-mutant, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New hope for kids with deadly brain tumors: combination drug trial launches

Disease control Recruiting now

This phase 2 trial is testing whether combining the drug ONC201 with other treatments (like paxalisib or a cancer-killing virus called DNX-2401) can help children and young adults with diffuse midline gliomas, a rare and aggressive brain cancer. The study enrolls 360 participants…

Matched conditions: RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT

Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control

Last updated Jun 28, 2026 00:00 UTC

Recurrent diffuse midline glioma, H3 K27M-mutant

Get alerted when new Recurrent diffuse midline glioma, H3 K27M-mutant trials appear

New hope for kids with deadly brain tumors: combination drug trial launches